DPP4 and metabolic dysfunction-associated steatohepatitis: Thus, DPP4 is important as a therapeutic target in HCC that arises from NASH and liver cirrhosis, but it remains unknown whether it is true for HCC that arises de novo in the otherwise healthy liver such as fibrolamellar HCC.